
Opinion|Videos|December 16, 2024
Managing CRS and ICANS: Approaches and Protocols
Key Takeaways
- Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
- Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Panelists discuss how clinical management of CAR T-cell therapy–associated toxicities focuses primarily on early recognition and prompt intervention with tocilizumab and/or corticosteroids for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), following established grading systems and treatment algorithms.
Advertisement
Episodes in this series

Video content above is prompted by the following
What is your approach to managing toxicities such as CRS and ICANS?
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine
2
The Side Door We Could Close: A Pharmacy Perspective on Menopause, Access, and the Leadership Pipeline
3
Tirzepatide Cuts MACE Risk in Diabetes With Heart Disease
4
CVS Health Expands GLP-1 Access With $29 Visits, Lilly Deal
5


































































































